Stock Track | Sino Biopharmaceutical Soars 5.09% Intraday on TRD205 Breakthrough Therapy Designation and Morgan Stanley Earnings Upgrade

Stock Track07-15 09:57

Sino Biopharmaceutical's stock surged 5.09% during intraday trading on Wednesday, following positive developments regarding its pipeline drug and analyst optimism.

The company announced that its subsidiary Beijing Tide Pharmaceutical's independently developed Class 1 new drug TRD205 has been granted Breakthrough Therapy Designation by China's Center for Drug Evaluation. This follows the completion of a Phase II clinical trial for chronic post-surgical neuropathic pain (CPSNP), a condition for which there is currently no specifically approved therapy. The drug's mechanism, which acts only on the peripheral nervous system, potentially avoids common adverse effects associated with central nervous system-targeting agents.

Adding to the positive sentiment, Morgan Stanley raised its earnings per share estimates for Sino Biopharmaceutical by 13.6%, 5.5%, and 3.9% for the years 2026 through 2028, respectively. The upgrade factors in expected licensing income from partnerships with Sanofi and GSK. The firm reiterated its Overweight rating on the stock with a target price of HKD 7.8.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1150561980?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 09:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150561980","market":"hk","top_or_hot":-1,"title":"Stock Track | Sino Biopharmaceutical Soars 5.09% Intraday on TRD205 Breakthrough Therapy Designation and Morgan Stanley Earnings Upgrade","media":"Stock Track","content":"<p>Sino Biopharmaceutical's stock surged 5.09% during intraday trading on Wednesday, following positive developments regarding its pipeline drug and analyst optimism.</p><p>The company announced that its subsidiary Beijing Tide Pharmaceutical's independently developed Class 1 new drug TRD205 has been granted Breakthrough Therapy Designation by China's Center for Drug Evaluation. This follows the completion of a Phase II clinical trial for chronic post-surgical neuropathic pain (CPSNP), a condition for which there is currently no specifically approved therapy. The drug's mechanism, which acts only on the peripheral nervous system, potentially avoids common adverse effects associated with central nervous system-targeting agents.</p><p>Adding to the positive sentiment, Morgan Stanley raised its earnings per share estimates for Sino Biopharmaceutical by 13.6%, 5.5%, and 3.9% for the years 2026 through 2028, respectively. The upgrade factors in expected licensing income from partnerships with Sanofi and GSK. The firm reiterated its Overweight rating on the stock with a target price of HKD 7.8.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Sino Biopharmaceutical Soars 5.09% Intraday on TRD205 Breakthrough Therapy Designation and Morgan Stanley Earnings Upgrade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Sino Biopharmaceutical Soars 5.09% Intraday on TRD205 Breakthrough Therapy Designation and Morgan Stanley Earnings Upgrade\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-07-15 09:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sino Biopharmaceutical's stock surged 5.09% during intraday trading on Wednesday, following positive developments regarding its pipeline drug and analyst optimism.</p><p>The company announced that its subsidiary Beijing Tide Pharmaceutical's independently developed Class 1 new drug TRD205 has been granted Breakthrough Therapy Designation by China's Center for Drug Evaluation. This follows the completion of a Phase II clinical trial for chronic post-surgical neuropathic pain (CPSNP), a condition for which there is currently no specifically approved therapy. The drug's mechanism, which acts only on the peripheral nervous system, potentially avoids common adverse effects associated with central nervous system-targeting agents.</p><p>Adding to the positive sentiment, Morgan Stanley raised its earnings per share estimates for Sino Biopharmaceutical by 13.6%, 5.5%, and 3.9% for the years 2026 through 2028, respectively. The upgrade factors in expected licensing income from partnerships with Sanofi and GSK. The firm reiterated its Overweight rating on the stock with a target price of HKD 7.8.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01177","symbol_name":"中国生物制药","start_time":0,"source_url":"","article_id":"1150561980","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150561980","pubTimestamp":1784080637,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Sino Biopharmaceutical's stock surged 5.09% during intraday trading on Wednesday, following positive developments regarding its pipeline drug and analyst optimism.The company announced that its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01177":"中国生物制药"},"translate_title":"股票追踪|中国生物制药因TRD205突破性疗法指定和摩根士丹利盈利上调，盘中飙升5.09%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1},"content_text":"Sino Biopharmaceutical's stock surged 5.09% during intraday trading on Wednesday, following positive developments regarding its pipeline drug and analyst optimism.The company announced that its subsidiary Beijing Tide Pharmaceutical's independently developed Class 1 new drug TRD205 has been granted Breakthrough Therapy Designation by China's Center for Drug Evaluation. This follows the completion of a Phase II clinical trial for chronic post-surgical neuropathic pain (CPSNP), a condition for which there is currently no specifically approved therapy. The drug's mechanism, which acts only on the peripheral nervous system, potentially avoids common adverse effects associated with central nervous system-targeting agents.Adding to the positive sentiment, Morgan Stanley raised its earnings per share estimates for Sino Biopharmaceutical by 13.6%, 5.5%, and 3.9% for the years 2026 through 2028, respectively. The upgrade factors in expected licensing income from partnerships with Sanofi and GSK. The firm reiterated its Overweight rating on the stock with a target price of HKD 7.8.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1150561980","isCrawlerRequest":true}